WATERTOWN, Mass., Oct. 29 /PRNewswire/ -- Enanta Pharmaceuticals Inc.
(www.enanta.com), a leading drug discovery company that focuses on
transforming existing drugs, natural products and biologically-active peptide
leads into small molecules with improved pharmacological properties presented
today its product development progress and a company overview at the Mass Opps
Investor Conference (Boston, MA). Dr. Spiros Jamas, President and CEO of
Enanta, discussed the company's current R&D programs for the development of
therapeutics for respiratory tract infections, asthma, psoriasis, and
Hepatitis C (HCV).
"Enanta is focusing on three product areas; macrolide antibiotics, novel
cyclosporin analogs and HCV protease inhibitors," said Spiros Jamas, President
and CEO of Enanta Pharmaceuticals. "We feel that these therapeutic areas
represent significant markets with unmet medical needs. Fueling Enanta's
progress is our chemistry-driven capability that we apply to transform
existing drugs, natural products and biologically active peptide leads into
small molecules with improved pharmacological properties."
Enanta has developed a new class of proprietary cyclosporine A analogs
with improved toxicity for the treatment of asthma and psoriasis. These
analogs can be applied topically, through inhalation to the lung, where they
exert a potent local anti-inflammatory effect by inhibiting T-cell activation
and proliferation. Enanta is also involved in the discovery of novel macrolide
antibiotics with improved antimicrobial and pharmacologic properties for the
treatment of respiratory tract infections. The company's macrolides have, to
date, shown potent activity against respiratory pathogens and excellent oral
bioavailability. Enanta is applying its macrocyclic chemistry expertise to the
discovery of novel HCV therapeutics and has entered into an exclusive
collaboration with Chiron Corporation (Sept. 4, 2002) that involves the
synthesis of compounds, structure-based drug design and testing of lead
compounds in enzyme assays, whole cell assays and animal models.
Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its
breakthrough chemistry technology -- Drug Morphing(TM) and Peptide Morphing(R)
-- to create new intellectual properties by transforming existing drugs,
natural products and biologically active peptides into novel small-molecule
drugs. The Company is initially focusing on new chemical entities derived from
existing drugs that address significant unmet medical needs: (a) new-
generation macrolide antibiotics to overcome bacterial resistance; and (b)
anti-inflammatory drugs for a variety of indications, including asthma,
psoriasis and inflammatory bowel diseases.
Make Your Opinion Count - Click Here
SOURCE Enanta Pharmaceuticals Inc.